Company intelligence / Profile preview

domaine privé

Ownership: Private
Development stage: Commercial

Overview

Domain Therapeutics has advanced its lead candidate DT–9081 into Phase I trials targeting solid tumors via EP4 antagonism. Other pipeline assets include preclinical anti–CCR8 antibodies and PAR₂ antagonists with differentiated mechanisms of action. The company's approach leverages deep expertise in GPCR biology to address unmet needs in cancer immunotherapy and inflammatory diseases through both small molecules and biologic modalities. Their bioSens-All® platform underpinning both internal R&D and external collaborations with major pharma partners.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeMonoclonal antibodyBiologicAntibodyAntagonist therapies targeting GPCRs
Industry: Biotech

Partnerships

Multiple partnerships with major biotech/pharma companies (>50 projects by DTNA as of recent years); specific names not disclosed publicly but includes academic consortia collaborations.

Beyond the preview

Go deeper on domaine privé.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on domaine privé.

Explore the full profile